Report cover image

Global Long-acting ESAs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 196 Pages
SKU # APRC20277709

Description

Summary

According to APO Research, The global Long-acting ESAs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting ESAs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Long-acting ESAs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Long-acting ESAs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Long-acting ESAs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Long-acting ESAs include Amgen, Cipla, CKD Pharma, Dr. Reddy's Laboratories, Kissei Pharmaceutical, Kyowa Hakko Kirin, Sanwa Kagaku Kenkyusho, Torrent Pharmaceuticals and Hansoh Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting ESAs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Long-acting ESAs, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting ESAs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting ESAs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-acting ESAs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-acting ESAs sales, projected growth trends, production technology, application and end-user industry.

Long-acting ESAs Segment by Company

Amgen
Cipla
CKD Pharma
Dr. Reddy's Laboratories
Kissei Pharmaceutical
Kyowa Hakko Kirin
Sanwa Kagaku Kenkyusho
Torrent Pharmaceuticals
Hansoh Pharma
Roche
Kyowa Kirin
Long-acting ESAs Segment by Type

Pegmolesatide
Methoxy Polyethylene Glycol-Epoetin Beta
Darbepoetin Alfa
Long-acting ESAs Segment by Application

Renal Anemia
Cancer
Other
Long-acting ESAs Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting ESAs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting ESAs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting ESAs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting ESAs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-acting ESAs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-acting ESAs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Long-acting ESAs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Long-acting ESAs Market Size, 2020 VS 2024 VS 2031
1.3 Global Long-acting ESAs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Long-acting ESAs Sales Estimates and Forecasts (2020-2031)
1.5 Global Long-acting ESAs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Long-acting ESAs Market Dynamics
2.1 Long-acting ESAs Industry Trends
2.2 Long-acting ESAs Industry Drivers
2.3 Long-acting ESAs Industry Opportunities and Challenges
2.4 Long-acting ESAs Industry Restraints
3 Long-acting ESAs Market by Manufacturers
3.1 Global Long-acting ESAs Revenue by Manufacturers (2020-2025)
3.2 Global Long-acting ESAs Sales by Manufacturers (2020-2025)
3.3 Global Long-acting ESAs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Long-acting ESAs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Long-acting ESAs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Long-acting ESAs Manufacturers, Product Type & Application
3.7 Global Long-acting ESAs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Long-acting ESAs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Long-acting ESAs Players Market Share by Revenue in 2024
3.8.3 2024 Long-acting ESAs Tier 1, Tier 2, and Tier 3
4 Long-acting ESAs Market by Type
4.1 Long-acting ESAs Type Introduction
4.1.1 Pegmolesatide
4.1.2 Methoxy Polyethylene Glycol-Epoetin Beta
4.1.3 Darbepoetin Alfa
4.2 Global Long-acting ESAs Sales by Type
4.2.1 Global Long-acting ESAs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Long-acting ESAs Sales by Type (2020-2031)
4.2.3 Global Long-acting ESAs Sales Market Share by Type (2020-2031)
4.3 Global Long-acting ESAs Revenue by Type
4.3.1 Global Long-acting ESAs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Long-acting ESAs Revenue by Type (2020-2031)
4.3.3 Global Long-acting ESAs Revenue Market Share by Type (2020-2031)
5 Long-acting ESAs Market by Application
5.1 Long-acting ESAs Application Introduction
5.1.1 Renal Anemia
5.1.2 Cancer
5.1.3 Other
5.2 Global Long-acting ESAs Sales by Application
5.2.1 Global Long-acting ESAs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Long-acting ESAs Sales by Application (2020-2031)
5.2.3 Global Long-acting ESAs Sales Market Share by Application (2020-2031)
5.3 Global Long-acting ESAs Revenue by Application
5.3.1 Global Long-acting ESAs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Long-acting ESAs Revenue by Application (2020-2031)
5.3.3 Global Long-acting ESAs Revenue Market Share by Application (2020-2031)
6 Global Long-acting ESAs Sales by Region
6.1 Global Long-acting ESAs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Long-acting ESAs Sales by Region (2020-2031)
6.2.1 Global Long-acting ESAs Sales by Region (2020-2025)
6.2.2 Global Long-acting ESAs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Long-acting ESAs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Long-acting ESAs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Long-acting ESAs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Long-acting ESAs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Long-acting ESAs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Long-acting ESAs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Long-acting ESAs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Long-acting ESAs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Long-acting ESAs Revenue by Region
7.1 Global Long-acting ESAs Revenue by Region
7.1.1 Global Long-acting ESAs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Long-acting ESAs Revenue by Region (2020-2025)
7.1.3 Global Long-acting ESAs Revenue by Region (2026-2031)
7.1.4 Global Long-acting ESAs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Long-acting ESAs Revenue (2020-2031)
7.2.2 North America Long-acting ESAs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Long-acting ESAs Revenue (2020-2031)
7.3.2 Europe Long-acting ESAs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Long-acting ESAs Revenue (2020-2031)
7.4.2 Asia-Pacific Long-acting ESAs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Long-acting ESAs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Long-acting ESAs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Amgen
8.1.1 Amgen Comapny Information
8.1.2 Amgen Business Overview
8.1.3 Amgen Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Amgen Long-acting ESAs Product Portfolio
8.1.5 Amgen Recent Developments
8.2 Cipla
8.2.1 Cipla Comapny Information
8.2.2 Cipla Business Overview
8.2.3 Cipla Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Cipla Long-acting ESAs Product Portfolio
8.2.5 Cipla Recent Developments
8.3 CKD Pharma
8.3.1 CKD Pharma Comapny Information
8.3.2 CKD Pharma Business Overview
8.3.3 CKD Pharma Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 CKD Pharma Long-acting ESAs Product Portfolio
8.3.5 CKD Pharma Recent Developments
8.4 Dr. Reddy's Laboratories
8.4.1 Dr. Reddy's Laboratories Comapny Information
8.4.2 Dr. Reddy's Laboratories Business Overview
8.4.3 Dr. Reddy's Laboratories Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio
8.4.5 Dr. Reddy's Laboratories Recent Developments
8.5 Kissei Pharmaceutical
8.5.1 Kissei Pharmaceutical Comapny Information
8.5.2 Kissei Pharmaceutical Business Overview
8.5.3 Kissei Pharmaceutical Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Kissei Pharmaceutical Long-acting ESAs Product Portfolio
8.5.5 Kissei Pharmaceutical Recent Developments
8.6 Kyowa Hakko Kirin
8.6.1 Kyowa Hakko Kirin Comapny Information
8.6.2 Kyowa Hakko Kirin Business Overview
8.6.3 Kyowa Hakko Kirin Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Kyowa Hakko Kirin Long-acting ESAs Product Portfolio
8.6.5 Kyowa Hakko Kirin Recent Developments
8.7 Sanwa Kagaku Kenkyusho
8.7.1 Sanwa Kagaku Kenkyusho Comapny Information
8.7.2 Sanwa Kagaku Kenkyusho Business Overview
8.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio
8.7.5 Sanwa Kagaku Kenkyusho Recent Developments
8.8 Torrent Pharmaceuticals
8.8.1 Torrent Pharmaceuticals Comapny Information
8.8.2 Torrent Pharmaceuticals Business Overview
8.8.3 Torrent Pharmaceuticals Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Torrent Pharmaceuticals Long-acting ESAs Product Portfolio
8.8.5 Torrent Pharmaceuticals Recent Developments
8.9 Hansoh Pharma
8.9.1 Hansoh Pharma Comapny Information
8.9.2 Hansoh Pharma Business Overview
8.9.3 Hansoh Pharma Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Hansoh Pharma Long-acting ESAs Product Portfolio
8.9.5 Hansoh Pharma Recent Developments
8.10 Roche
8.10.1 Roche Comapny Information
8.10.2 Roche Business Overview
8.10.3 Roche Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Roche Long-acting ESAs Product Portfolio
8.10.5 Roche Recent Developments
8.11 Kyowa Kirin
8.11.1 Kyowa Kirin Comapny Information
8.11.2 Kyowa Kirin Business Overview
8.11.3 Kyowa Kirin Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Kyowa Kirin Long-acting ESAs Product Portfolio
8.11.5 Kyowa Kirin Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Long-acting ESAs Value Chain Analysis
9.1.1 Long-acting ESAs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Long-acting ESAs Production Mode & Process
9.2 Long-acting ESAs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Long-acting ESAs Distributors
9.2.3 Long-acting ESAs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.